Company intelligence / Profile preview
Edgewise Therapeutics
Boulder, Colorado, United Statesedgewisetx.com ↗
- Ownership
- Public · EWTX
- Employees
- ~110
- Development stage
- Phase 2
01
Overview
Edgewise Therapeutics has reported positive topline results from its Phase 2 CIRRUS-HCM trial of EDG‑7500 in hypertrophic cardiomyopathy. The drug met its primary endpoint by reducing left ventricular outflow tract gradient without significant changes to ejection fraction. However, some patients experienced side effects including dizziness and atrial fibrillation; two cases required cardioversion. Sevasemten (EDG‑5506) continues late-stage development for Becker and Duchenne muscular dystrophies with a focus on preserving muscle function.
- Therapeutic areas
- Rare DiseasesCardiovascular
- Modalities
- small molecules
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
03
Partnerships
No major disclosed pharmaceutical or biotech partnerships as of the latest updates.
04
Financials
- Market cap
- $4.2B
- Total revenue
- $0
- Enterprise value
- $2.4B
Beyond the preview
Go deeper on Edgewise Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Edgewise Therapeutics.